Onureg (azacitidine tablets) Patient Assistance Program
Don’t let the high cost of brand oral azacitidine maintenance disrupt your AML treatment. We help eligible patients access Onureg (azacitidine tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Onureg (azacitidine tablets) is FDA-approved for continued treatment of adults with acute myeloid leukemia (AML) in first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and who are not able to complete intensive curative therapy (e.g., allogeneic stem cell transplant). Oral azacitidine maintenance — first approved oral hypomethylating agent for AML maintenance. The QUAZAR AML-001 trial demonstrated improved overall survival vs placebo as post-remission maintenance.
- Without assistance, Onureg costs commonly run approximately $20,000–$27,000 per month.
- Through AffordMyPrescriptions, qualifying patients can access Onureg for a flat $69.95 per month.
- Note: Onureg is NOT bioequivalent to injectable azacitidine (Vidaza or generic) — different PK and indications. Injectable azacitidine (Vidaza — generic now widely available, very cheap) is used for MDS, CMML, AML therapy (not maintenance). For AML therapy: Venclexta (venetoclax) + hypomethylating agent (azacitidine or decitabine — both generic) for newly diagnosed not eligible for intensive chemo (VIALE-A); intensive chemotherapy (7+3, FLAG-IDA) for fit patients; targeted therapy for specific mutations (IDH1 — ivosidenib/Tibsovo + azacitidine; IDH2 — enasidenib/Idhifa; FLT3 — midostaurin/Rydapt for induction, gilteritinib/Xospata for R/R; menin inhibitors for KMT2A/MLL or NPM1 — revumenib/Revuforj); allogeneic SCT for fit patients with appropriate risk. For MDS: azacitidine (generic), decitabine + cedazuridine (Inqovi — oral), luspatercept (Reblozyl), lenalidomide for del(5q).
What is Onureg Prescription Assistance Program?
The Onureg Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Onureg (used for AML maintenance in first CR/CRi after intensive induction in patients not proceeding to transplant) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, hematology coordination, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing AML in remission.
At AffordMyPrescriptions, our Patient Advocates handle the entire Onureg PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your hematologist for required medical documentation, follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification — so you never face a gap in your Onureg AML maintenance therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Onureg enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your AML maintenance treatment.
Pharmacy Price Comparison
- Without assistance, Onureg costs thousands of dollars per month at specialty pharmacies. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this AML maintenance therapy accessible if you qualify. The table below compares typical retail pricing across major pharmacies to what you'd pay with our Onureg advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Generic decitabine IV (alt) | ~$200/dose | Alt HMA — different indication |
| Walgreens | ~$26,000/mo | Save substantially |
| CVS Pharmacy | ~$27,000/mo | Save substantially |
| Walmart | ~$21,000/mo | Save substantially |
| Specialty pharmacy | ~$20,000/mo | Save substantially |
| Generic azacitidine IV (NOT bioequivalent) | ~$200/dose | Different indication & PK |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Onureg — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Onureg Prescription Program?
The Onureg Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Important: Onureg (oral azacitidine) is NOT bioequivalent to injectable azacitidine — they cannot be substituted.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Onureg assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Onureg is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Onureg:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $20,000–$27,000 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Onureg assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Onureg Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Onureg:
Onureg is oral azacitidine — pharmacokinetically distinct from injectable azacitidine (Vidaza) and indicated specifically for AML maintenance therapy after first complete remission. Oral hypomethylating agent reactivates tumor suppressor genes through DNA demethylation. The QUAZAR AML-001 trial established improved overall survival vs placebo as post-remission maintenance in patients not proceeding to allogeneic SCT.
How It Works:
Acute myeloid leukemia (AML) commonly involves DNA hypermethylation of tumor suppressor genes — silencing critical regulatory pathways. After induction chemotherapy achieves complete remission, residual disease drives relapse — particularly in older patients or those with poor-risk biology who are not transplant candidates. Azacitidine is a pyrimidine nucleoside analog incorporated into DNA — inhibits DNA methyltransferase, leading to hypomethylation of DNA and re-expression of tumor suppressor genes. Oral formulation (Onureg) achieves PK profile suitable for chronic maintenance dosing — sustained low-level hypomethylating exposure that may suppress measurable residual disease and delay relapse. Maintenance dosing (14 days of 28-day cycle) until progression.
Form and Use:
Onureg 300 mg or 200 mg tablets. Recommended dose 300 mg once daily on days 1–14 of each 28-day cycle. May reduce to 200 mg for tolerability. Take with or without food at the same time each day. Take antiemetics for first 2 cycles minimum. Continue until disease progression or unacceptable toxicity. Periodic CBC, comprehensive metabolic panel.
Generic Availability:
No generic Onureg. Important — Onureg (oral azacitidine) is NOT bioequivalent to injectable azacitidine (Vidaza or generic injectable azacitidine). Different PK profile, different indications, different dosing schedules. Injectable azacitidine (Vidaza/generic — very cheap, ~$200/dose) is used for MDS, CMML, AML therapy (not maintenance per Onureg indication). For AML therapy: Venclexta (venetoclax) + hypomethylating agent (azacitidine or decitabine — both generic IV) for newly diagnosed not eligible for intensive chemo (VIALE-A trial); intensive chemotherapy 7+3 (cytarabine + anthracycline) or FLAG-IDA for fit patients (all generic chemotherapy backbones); targeted therapy for specific mutations — IDH1 (ivosidenib/Tibsovo + azacitidine for IDH1-mutated newly diagnosed AML per AGILE), IDH2 (enasidenib/Idhifa for IDH2-mutated relapsed/refractory), FLT3 (midostaurin/Rydapt for FLT3-mutated newly diagnosed with intensive chemo per RATIFY, gilteritinib/Xospata for FLT3-mutated relapsed/refractory per ADMIRAL), menin inhibitors for KMT2A/MLL rearranged or NPM1-mutated (revumenib/Revuforj). Allogeneic SCT for fit patients with appropriate risk. For MDS: azacitidine generic, decitabine + cedazuridine (Inqovi — oral), luspatercept (Reblozyl) for transfusion-dependent anemia, lenalidomide (Revlimid generic) for del(5q) MDS, supportive care.
Warnings:
Bone marrow suppression (cytopenias — neutropenia, thrombocytopenia, anemia; monitor CBC; hold for severe; manage infections aggressively), tumor lysis syndrome (high disease burden — monitor labs, hydrate, consider allopurinol), embryo-fetal toxicity (men and women — effective contraception during therapy and for several months after). Other: nausea, vomiting, diarrhea (proactive antiemetic management critical for first 2 cycles minimum), fatigue, decreased appetite, abdominal pain, dyspnea, peripheral edema, infections. Counsel patients on importance of differentiation from injectable azacitidine — patients should not substitute or switch without prescriber guidance.
FAQ (Frequently Asked Questions)
How much does Onureg cost without insurance?
$20,000–$27,000 per month. Annual cost can exceed $250,000 — among the more expensive maintenance therapies. Specialty pharmacy and Patient Assistance Programs are essential.
Is Onureg the same as injectable azacitidine (Vidaza)?
No — Onureg (oral azacitidine) is NOT bioequivalent to injectable azacitidine (Vidaza or its generic). Different PK profile, different dosing schedules, different FDA-approved indications. Patients should not substitute or switch between oral and injectable forms without prescriber direction. Injectable generic azacitidine is much cheaper but is used for MDS, CMML, and AML therapy — not the AML maintenance indication of Onureg.
Why is Onureg specifically for AML maintenance after first remission?
The QUAZAR AML-001 trial enrolled patients with AML in first complete remission after intensive induction chemotherapy who were not proceeding to allogeneic transplant — Onureg maintenance improved overall survival vs placebo. The FDA approval reflects this specific patient population and clinical scenario.
Why don't patients just take generic injectable azacitidine instead?
Different PK profile and clinical evidence base. Injectable azacitidine 7-day dosing achieves higher peak levels with shorter exposure; oral azacitidine 14-day dosing achieves lower sustained exposure — biologically different. The maintenance OS benefit was demonstrated specifically with oral azacitidine (Onureg) — extrapolating to injectable azacitidine is not appropriate per labeling.
Why should I consider stem cell transplant before maintenance?
Allogeneic stem cell transplantation remains the only potentially curative therapy for many AML patients, particularly those with intermediate or adverse-risk disease. Transplant eligibility evaluation should occur during initial induction and consolidation. Onureg maintenance is for patients in CR/CRi who are NOT proceeding to transplant — typically older or unfit patients, or those without suitable donor.
Take Control of Your Medication Costs
AML maintenance therapy for patients in first remission should not be derailed by cost. Onureg (oral azacitidine) is uniquely indicated and is NOT interchangeable with injectable azacitidine. Our Onureg advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Onureg through a Patient Assistance Program, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.